Cefdinir
FDA-approved product (capsule, oral), marketed as Cefdinir, Omnicef.
- Registered studies
- 32
- Lab records
- 8
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Chronic bronchitis
- Infection
- Infectious otitis media
- Otitis media
- Pharyngitis
- Pneumonia
- Recurrent tonsillitis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Third-generation cephalosporins
- FDA pharmacologic class
- Cephalosporin Antibacterial FDA label ↗
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01DD15; FDA class Cephalosporin Antibacterial
Repurposing investigation
Cefdinir is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA99.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli99.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae98.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis47.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
32registered studies name this medicine, for any condition. See them below.
Experimental
- MRSA: measured active in 2 of 2 lab records
- E. coli: measured active in 4 of 4 lab records
- K. pneumoniae: measured active in 2 of 2 lab records
Show the 8 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Cefdinir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Micafungin SodiumExisting use: Candidiasis52.4% AI-predicted activityagainst E. coli50+ registered studies
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm52.3% AI-predicted activityagainst E. coli50+ registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more52.2% AI-predicted activityagainst E. coli50+ registered studies
- Ponatinib HydrochlorideExisting use: Acute lymphoblastic leukemia, Chronic myelogenous leukemia, Lymphoid leukemia and 1 more52.2% AI-predicted activityagainst E. coli50+ registered studies
- FinerenoneExisting use: Cardiovascular disease, Chronic kidney disease, Type 2 diabetes mellitus52.2% AI-predicted activityagainst E. coli50+ registered studies
- Bromocriptine MesylateExisting use: Acromegaly, Adenoma, Hyperprolactinemia and 4 more52.2% AI-predicted activityagainst E. coli50+ registered studies
- CrizotinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma52.0% AI-predicted activityagainst E. coli50+ registered studies
- Edoxaban TosylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 3 more52.0% AI-predicted activityagainst E. coli22 registered studies
- PimecrolimusExisting use: Atopic eczema, Eczematoid dermatitis51.9% AI-predicted activityagainst E. coli50+ registered studies
- Quizartinib DihydrochlorideExisting use: Acute myeloid leukemia, Myeloid leukemia51.8% AI-predicted activityagainst E. coli4 registered studies
- TucatinibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 6 more51.6% AI-predicted activityagainst E. coli50+ registered studies
- Dabigatran Etexilate MesylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 5 more51.4% AI-predicted activityagainst E. coli14 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Comparative, Single-Center, Pediatric Taste Test Study of Omnicef Versus Amoxicillin Antibiotic Suspension Medications
NCT00645125 · start 2003-01
Registered record
- Registry ID
- NCT00645125
- Conditions
- Healthy
- Interventions
- cefdinir (Omnicef); amoxicillin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2003-01
- Completion
- Not recorded
- Enrolment
- 154
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventioncefdinir (Omnicef); amoxicillinPhasePhase 4Registry statusCompletedSafety and Efficacy Study of Cefdinir Oral Suspension, in Pediatric Subjects to Treat Acute Otitis Media
NCT00645203 · start 2002-07
Registered record
- Registry ID
- NCT00645203
- Conditions
- Acute Otitis Media
- Interventions
- cefdinir
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2002-07
- Completion
- Not recorded
- Enrolment
- 447
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Otitis MediaInterventioncefdinirPhasePhase 2 / Phase 3Registry statusCompleted